- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 239/48 - Two nitrogen atoms
Patent holdings for IPC class C07D 239/48
Total number of patents in this class: 1106
10-year publication summary
|
92
|
69
|
79
|
55
|
63
|
46
|
53
|
32
|
26
|
4
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Rigel Pharmaceuticals, Inc. | 522 |
36 |
| Bristol-myers Squibb Company | 4795 |
35 |
| Signal Pharmaceuticals, LLC | 177 |
34 |
| Boehringer Ingelheim International GmbH | 4595 |
22 |
| Novartis AG | 10494 |
20 |
| Janssen Sciences Ireland UC | 174 |
19 |
| Merck Patent GmbH | 5727 |
16 |
| Korea Research Institute of Chemical Technology | 1432 |
15 |
| Alexion Pharmaceuticals, Inc. | 645 |
14 |
| Afferent Pharmaceuticals, Inc. | 25 |
13 |
| Dana-Farber Cancer Institute, Inc. | 2640 |
13 |
| H. Lee Moffitt Cancer Center and Research Institute, Inc. | 997 |
13 |
| Celgene Avilomics Research, Inc. | 31 |
12 |
| Corteva Agriscience LLC | 2663 |
12 |
| Takeda Pharmaceutical Company Limited | 2710 |
11 |
| Portola Pharmaceuticals, Inc. | 87 |
11 |
| FUJIFILM Corporation | 30010 |
10 |
| Roche Palo Alto LLC | 66 |
10 |
| Genentech, Inc. | 4040 |
9 |
| AstraZeneca AB | 2833 |
9 |
| Other owners | 772 |